Harmony Biosciences (HRMY) Q1 2026: OpEx Jumps 38% as Business Development and Pipeline Investment Accelerate
Harmony Biosciences’ first quarter saw a sharp increase in operating expenses, driven by licensing and pipeline investment, as the company doubled down on its four-pillar strategy to secure long-term growth and defend its core franchise. Management’s renewed business development focus, combined with ongoing litigation to protect exclusivity, sets the stage for a pivotal period as pipeline data and deal execution will determine the trajectory into the next decade.
Summary
- Business Development Prioritization: Renewed commitment to transactions aims to bolster near-term and long-term revenue.
- Pipeline Investment Surge: R&D and licensing spend signals intent to diversify beyond core narcolepsy franchise.
- IP Defense Intensifies: Multi-layered litigation and new patent suits are critical to maintaining exclusivity into 2030.
Business Overview
Harmony Biosciences is a central nervous system (CNS) biopharma company focused on commercializing and developing therapies for rare neurological disorders. The company’s primary revenue driver is WAKIX (pitolisant), a treatment for narcolepsy, which accounts for the vast majority of net sales. Harmony is expanding its pipeline with assets such as BP205, an orexin-2 agonist for sleep-wake and broader CNS indications, and is actively pursuing business development to extend its reach into adjacent CNS and rare disease markets.
Performance Analysis
First quarter results reflect robust underlying demand for WAKIX, with net sales up year-over-year, despite typical seasonal headwinds from payer and market access dynamics that impact patient starts in Q1. Importantly, the company reported a significant increase in cost of goods sold as a percentage of net sales, attributed almost entirely to new royalties under the Novidium license, which also provides new development opportunities in CNS.
Operating expenses surged 38% year-over-year, largely due to a $32 million upfront licensing payment for the amorphous form of pitolisant, as well as continued R&D and commercialization investments. Excluding these one-time licensing costs, underlying operating expense growth was a more modest 5%. Cash flow was muted by these outflows and a reduction in accrued expenses, but management expects reacceleration in coming quarters as licensing costs normalize. The company ended the quarter with $870.5 million in cash and $160 million in debt, providing significant capacity for business development.
- Gross Margin Compression: New royalty obligations from Novidium increased cost of goods sold, pressuring margins.
- Expense Discipline (Ex-Licensing): Core operating expense growth remains contained outside of business development outlays.
- Cash Position Strength: Ample liquidity enables continued pipeline and acquisition activity without near-term financing risk.
WAKIX franchise momentum remains strong, with Q1 patient demand exceeding prior year levels and management reiterating full-year revenue guidance. Persistency and payer coverage remain stable, supporting the outlook for continued franchise durability.
Executive Commentary
"I have shared with you our four pillars of value creation that we feel matter most to investors and will serve as the framework by which our performance will be measured. First, protect the Pitocin franchise into the 2030s. Second, continued growth of the Pitocin franchise in an evolving market. Third, drive value from our robust pipeline centered around BP205, our potential best-in-class orexin-2 agonist. And last, a renewed emphasis on business development with our goal to transact."
Dr. Jeff Dano, President and Chief Executive Officer
"It's our intent to deploy cash into business development with the objectives of enhancing revenues in the 2028 to 2032 timeframe, consistent with our four key pillars of value creation for shareholders."
Glenn, Chief Financial Officer
Strategic Positioning
1. Multi-Layered IP Defense
Harmony is aggressively defending its WAKIX exclusivity through a multi-pronged legal strategy, including ongoing ANDA litigation and a new amorphous patent suit. Management’s confidence in the strength of its IP estate, covering both crystalline and amorphous forms, is central to maintaining market exclusivity into 2030, including pediatric extension. The approach is designed to deter at-risk launches and protect the franchise’s cash flows.
2. Pipeline Advancement and Differentiation
BP205, a highly potent orexin-2 agonist, is positioned as a potential best-in-class therapy for sleep-wake disorders and broader CNS indications. The program is advancing through multiple ascending dose and food effect studies, with pivotal PK data expected mid-year. Management emphasizes the compound’s potency, safety, and once-daily dosing as key differentiators, while also exploring additional indications such as mood, cognition, and ADHD in preclinical work.
3. Renewed Business Development Focus
Management signaled a renewed organizational commitment to business development, targeting near-term revenue-generating assets in CNS, sleep-wake, and epilepsy. The company is open to M&A, licensing, and collaborations, leveraging its strong cash position and commercial infrastructure. The intent is to supplement organic growth with bolt-on deals that can drive accretive returns and diversify the revenue base as WAKIX matures.
4. Commercial Execution and Franchise Resilience
WAKIX continues to deliver steady growth despite Q1 seasonality, with persistency rates and payer coverage remaining stable. The commercial team’s track record provides a platform for future launches or in-licensed assets, supporting management’s confidence in scaling new products efficiently.
Key Considerations
This quarter’s results underscore a strategic inflection point, as Harmony balances franchise protection with pipeline risk and external deal-making:
Key Considerations:
- IP Litigation Outcomes: The timeline and outcome of ongoing and new patent lawsuits will determine exclusivity duration and competitive dynamics for WAKIX.
- Pipeline Data Readouts: Mid-year PK data for BP205 and progress in preclinical CNS indications are critical for future growth visibility.
- Deal Execution Risk: The ability to source and close value-accretive transactions, particularly those with near-term revenue, will test management’s BD strategy.
- Margin Pressures: Rising royalties and R&D spend could weigh on profitability if not offset by top-line growth or new revenue streams.
Risks
Harmony faces material risks from ongoing generic litigation, margin compression due to rising royalties, and execution on both pipeline and business development fronts. The crowded orexin agonist landscape raises the bar for clinical differentiation, while delays or setbacks in litigation could expose the core franchise to earlier-than-expected competition. Deal execution risk is elevated, given management’s stated urgency and the need for accretive returns.
Forward Outlook
For Q2 and the remainder of 2026, Harmony guided to:
- Full-year net sales of $1 billion to $1.04 billion, reiterating prior guidance.
- Continued ramp in R&D expense as BP205 and other trials accelerate.
For full-year 2026, management maintained guidance:
- Top-line growth driven by WAKIX, with margin headwinds from higher royalties and licensing fees.
Management highlighted several factors that will shape results:
- Expected stabilization of operating expenses after one-time licensing payments.
- Potential for business development transactions to supplement organic growth in the 2028-2032 window.
Takeaways
Harmony’s quarter marks a shift toward aggressive investment in pipeline and business development, while defending its flagship franchise through layered IP litigation.
- Margin and Expense Shift: Royalties and licensing costs are pressuring margins, but underlying expense discipline is intact outside of these investments.
- Strategic Execution in Focus: The next 12-18 months will test management’s ability to deliver on both clinical and business development milestones, which are critical for long-term value creation.
- Investor Watchpoint: Track pipeline data, litigation developments, and the pace and quality of business development deals as key drivers of the company’s forward trajectory.
Conclusion
Harmony Biosciences is entering a decisive phase, balancing near-term franchise protection with long-term growth bets in pipeline and business development. Execution on IP defense, clinical milestones, and accretive deal-making will determine whether the company can sustain and diversify its revenue base as WAKIX matures.
Industry Read-Through
Harmony’s quarter highlights the growing importance of IP strategy and business development in specialty pharma, particularly for companies with a single-product focus facing upcoming patent cliffs. The company’s approach to layered exclusivity, aggressive pipeline investment, and readiness to transact on near-term revenue assets sets a template for peers in CNS and rare disease. The competitive intensity in orexin agonists and the need for differentiated clinical profiles signal that innovation and execution will be paramount for success in the evolving sleep-wake and CNS landscape. Investors in the sector should watch for similar moves by other specialty biopharma companies as they seek to extend product life cycles and diversify pipelines through both internal and external means.